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1.1. Need for developing case definitions and guidelines for data
collection, analysis, and presentation for neurodevelopmental delay as
an adverse event following immunization
Neurodevelopmental delay (NDD) is a term used to describe
delays in skill development of infants and young children. Termi-
7624 A.N. Villagomez et al. / Vaccine 37 (2019) 7623–7641nology and definitions of NDD vary broadly in the literature, though
all are used to signify a delay in one or more developmental
domains compared to typical development. This paper focuses on
defining NDD to assist in the identification of developmental delays
as potential adverse events following maternal immunization.
1.1.1. Neurodevelopment
Early child neurodevelopment refers to the organization and
function of the central nervous system (CNS). The development
of the CNS starts early in embryonic life and continues for years
after birth. Processes, such as dendritic pruning, myelination, and
the growth of an extensive and complex system of connections
accelerate during early childhood and persist into adulthood [1].
The early rapid and complex development of the brain underlies
the functional or observable performance and abilities in the child.
The pattern and timing of neurodevelopmental skill attainment
is similar for most children [1]. For example, during the first three
years of life, early development is marked by enormous gains in
gross motor abilities (e.g., rolling, standing, walking), fine-motor
coordination (e.g., self-feeding, pincer grasp, drawing lines and cir-
cles), language abilities (e.g. orienting to familiar voices, babbling,
following a simple command, first words, expanding vocabulary),
and markedly improved ability to solve increasingly complex prob-
lems. The development of each skill influences the development of
others. For example, gross motor skill development allows children
greater opportunities for exploration and social interaction which
promotes language growth [2–4]. Likewise, increased language
capacity promotes the development of cognitive control [5,6].
Both biological and environmental factors can influence neu-
rodevelopmental trajectories in positive and negative ways
throughout the lifespan, beginning as early as the embryonic period,
with observable differences in development and functioning nota-
ble as early as the antenatal period [7]. For example, genetic disor-
ders, chromosomal abnormalities, infections, perinatal brain
injuries, and alterations in neuronal migration may impact brain
development and result in NDD. Poverty, insufficient cognitive
stimulation, and malnutrition are significant environmental risk
factors for atypical neurodevelopment [8]. Ultimately, biological
and environmental factors interact. For instance, environmental
risk factors can exacerbate existing biological vulnerabilities, or
environmental factors can improve neurodevelopmental outcomes
despite biological vulnerabilities. Environmental factors such as
good nutrition, environmental stimulation, and maternal factors,
includingmaternal education level and responsiveness, are particu-
larly protective and support a positive developmental trajectory [9].
There are specific time periods in which the brain is more sen-
sitive or vulnerable to biological and environmental influences
which can affect the long-term trajectory of the developing brain
[10,11]. This is particularly the case during gestation and early life
[12,13]. For example, alterations in neuronal migration in utero
have been associated with movement problems, developmental
dyslexia, and other developmental delays [14,15]. Zika virus is a
recent example of devastating developmental sequelae to brain
development from in utero infection resulting in microcephaly
and potentially more subtle effects if the virus is contracted later
in life [16]. Similarly, many studies have found an association
between responsive caregiving in sensitive periods of early child-
hood with improved self-regulatory skills later in life [17,18].
A NDD is therefore the result of atypical central nervous system
development that can occur at any point in utero through the early
developmental period up to approximately 5 years of age. The
effects of atypical neurodevelopment may impact one area of func-
tioning (e.g., language) or multiple areas (e.g., motor, language, and
cognitive). The appropriate and accurate identification of NDDs in
infants and young children has important implications for the indi-
vidual and for public health, including the ability to efficiently allo-cate available resources, implement early preventive and
therapeutic interventions, and monitor health interventions and
programs[19].
1.1.2. Cultural and universal determinants of neurodevelopment
Developmental psychology has long debated how a child’s neu-
rodevelopmental trajectory is influenced by biological determi-
nants (i.e., nature) and how much is environmentally influenced
(i.e., nurture). More specifically, can developmental skill expecta-
tions be universally applied or are they primarily determined by
culture and experience? Research has demonstrated that the
answer is both nature and nurture, as well as their interplay, with
some areas of neurodevelopment more or less influenced by the
context of the child’s culture and social practices than other areas
[20]. For example, motor skills tend to develop more similarly
across cultures [21], whereas the development of social skills
may be more variable and dependent on the cultural context,
norms, and expectations [20,22].
Multiple studies have demonstrated the influence of culture on
neurodevelopmental skill development [23,24]. For example, a
child’s language skills in the school years are correlated with
responsive caregiving and the amount of direct speech input the
child receives in the first years of life [25]. In turn, the amount of
speech a caregiver directs to his/her child in those early years is
influenced by the cultural beliefs around child rearing and the
socialization of children. Clearly, cultures vary in the importance
placed on certain skills, which subsequently influences both the
amount of opportunities available to a child for practice and also
the level of adult support provided to foster development of those
skills. This, in turn, may influence the trajectory of that skill or the
development of that skill at the expense of another [26]. For exam-
ple, some cultures place a value on skills such as numeracy and
writing in school and in the workplace. Therefore, the development
of these skills may be prioritized by caregivers more in the early
years over the development of others, such as integrating well into
the community, which may be considered more important and rel-
evant in another cultural context [27].
Although culture clearly influences developmental skills, stud-
ies also show that development usually follows the same progres-
sive patterns globally even though the ages of attainment may vary
[22,28–32]. Additionally, when sufficient opportunity and stimula-
tion are present and developmental risk factors are minimized, the
commonalities across cultural groups in developmental skills
increases. A series of studies conducted in Peru, Canada and India
have demonstrated that when risk factors are minimized, children
between the ages of 1 and 3 years develop similar foundational
social-cognitive skills (e.g., imitation, communicative pointing)
around the same age across cultural settings [33]. Global common-
alities and a universally applied understanding of neurodevelop-
mental skills may be more applicable in the period of infancy
and early childhood than during later years as culture appears to
play an increasingly important role [33].
1.1.3. Causes and background rates of NDD
Understanding the incidence of NDD across the world is compli-
cated by several factors. Barriers to assessment and health care
access in low- and lower middle-income countries (LMICs), as well
as for certain groups in high-income countries (HICs) can compli-
cate the ability to ascertain true incidence rates [34–37]. Data col-
lection methods can vary substantially and may not include direct
measurement, but instead rely on caregiver report of a child’s pre-
vious diagnosis of NDD, caregiver report on a developmental
screeningmeasure, or other governmental data, such as service uti-
lization [34,36,38–43]. Lastly, many studies reporting on rates of
NDD include a large age range or other neurodevelopmental and
medical disorders and sensory and motor impairments, which are
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age and domain specific information more difficult to obtain [34].
Due to these issues, it can be difficult to compare rates of NDD
even in HICs with presumably greater resources. In the United
States between 2014 and 2016, an estimated 4.67% of children ages
3–7 years were identified as having a NDD, excluding children
with neurodevelopmental disorders, such as autism and intellec-
tual disability [38]. In the United Kingdom, using a broader defini-
tion of developmental delay for a cohort of children born between
2000 and 2002, an estimated 10% of children 9 months of age had
mild delays with an additional 2% identified as having more severe
delays [44]. Data from 2009 in Australia estimated 7.0% of children
ages 0–14 years met criteria for a broader definition of disability
encompassing developmental delays, medical problems and sen-
sory and motor impairments [45]. Again, these estimates vary
according to definition of NDD, method of data collection, and ages
of the children studied.
A paucity of data regarding rates of neurodevelopmental delay in
LMICs has resulted in model-based estimates of burden. Current
estimates suggest that approximately 43% of children under 5 years
living in LMICs fail to reach their cognitive potential because of fac-
tors such as poverty, illness, poor nutrition, and lack of stimulating
care [46]. Data collected on the Early Childhood Development Index
(ECDI) between 2005 and 2015 from almost 100,000 3 and 4-year-
old children in 35 LMICs showed 14.6% of children performing
poorly in the cognitive domain, 26.2% in the socioemotional domain
and 36.8% of children performing poorly on either or both domains.
Children living in Sub-Saharan Africa, South Asia, East Asia and the
Pacific region were at the greatest risk [47].
It is clear that the risk varies substantially for children depend-
ing on where they live in the world and that estimates of neurode-
velopmental problems in LMICs are much higher than in HICs
because of the increased exposure to these risk factors. While rates
of poverty have decreased globally [48], which should lower the
risk for NDD, high rates of NDD remain in many parts of the world
where few resources are available for screening, treatment and
intervention [19]. Advances in medical care have contributed to
reduced rates of NDD in regions in which they are available. In
parts of the world in which this level of care cannot be accessed,
ongoing risk factors remain. For example, improved antenatal,
perinatal, and neonatal care and access to early treatment of
various infections, such as cerebral malaria or meningitis have con-
tributed to better developmental outcomes [36,49,50]. Conversely,
NDD rates have risen in some parts of the world where better
access to medical care has contributed to increased rates of sur-
vival, including for premature birth and for some infections, such
as HIV [37,38,51,52]. Some common causes of NDD are described
in Table 1.
1.1.4. Medical evaluation of causes of developmental delay
With a broad spectrum of potential causes for developmental
delay, a comprehensive medical evaluation can provide insights
to commonly associated conditions. Physical exam findings may
make certain diagnoses (e.g., Down Syndrome) evident in the new-
born period, while other diagnoses (e.g., Fragile X) may be diag-
nosed at a later age. Genetic testing may include analysis via
chromosomal microarray, whole exome sequencing, or karotype.
Evaluation for various inborn errors of metabolism may include
testing of blood and urine specimens. Neuroimaging (e.g., magnetic
resonance imaging) may provide utility for the identification of
neurologic abnormalities and/or injury. Additionally, delays in
specific domains, such as speech and language, may be closely
related to other medical conditions, such as hearing deficits. A
complete description of the medical assessment of infants and chil-
dren with developmental delays is beyond the scope of this review,
and guidance is available elsewhere [82].1.1.5. Limitations of neurodevelopmental assessment in LMIC
Much of the difficulty in gathering data about rates of NDD
globally is related to barriers in assessment. While resources to
identify and evaluate NDD in children 0–5 years of age are often
available in HICs, barriers in health systems and infrastructure,
lack of appropriate assessment tools, and other child and family
factors challenge this process in LMICs.
Within health systems in LMICs, there is often a shortage of
appropriately qualified providers to conduct standardized assess-
ments. Furthermore, most medical professionals, who are most
often the primary health care providers of children, are trained to
treat acute childhood illnesses, but not to evaluate and recognize
NDDs [37]. When available, providers with training in early child-
hood assessment are often located in larger cities resulting in addi-
tional barriers for children living in rural areas [83]. Providers may
also feel ethically challenged with diagnosing neurodevelopmental
problems when there are limited options for treatment or inter-
vention [83,84]. Compounding difficulties related to qualified
examiners, the health care infrastructure infrequently provides
ideal environments (e.g., quiet and private space with limited dis-
tractions) to conduct neurodevelopmental assessments.
The lack of availability of neurodevelopment assessment mea-
sures in LMICs is also a significant barrier to assessment. Tools
may not be available in the local language, and when available,
maynothaveadequately establishednormativedata.Most available
measures have beendeveloped inHICs [85], and translated for use in
LMICs [34]. Therefore, cultural relevancewith regard to test content
andmaterials, aswell asmethods of administrationmay not be ade-
quately addressed [34,86,87]. This can amplify cultural differences
and limit the validity of test findings [88–92]. Additionally, the psy-
chometric properties of tests developed in HICs, including sensitiv-
ity, specificity, reliability, and validity, may be problematic when
applied for use in LMICs [34,93,94]. Despite these concerns, creating
new tests with sound psychometrics, and developing normative
standards, is costly and can take several years, especially in LMICs
where resources are often limited [34,95,96].
Engaging children in direct neurodevelopmental assessment
can also prove challenging in LMICs due to their often limited
experience completing such tasks and possible anxiety or fear
around working with a health professional [93]. Differing cultural
beliefs of the provider or family can also impact early recognition
or identification of a NDD [85,97–101]. Low rates of diagnosis of
certain developmental disorders, such as autism spectrum disor-
ders, may be indicative of the community’s ‘‘tolerance” for a cer-
tain degree of behavior differences, rather than an indication that
such behaviors are not observed at comparable rates across cul-
tures [98]. Conversely, in high risk environments where NDDs
are highly prevalent, caregivers may not have a reference for nor-
mative child development. Other barriers to reliable and valid
assessment of neurodevelopment include caregiver literacy/com-
prehension and concerns around stigmatization, which can limit
the use of written questionnaires, checklists, and answers to inter-
view questions [85,102]. These factors can also influence families’
willingness to bring their children for neurodevelopment assess-
ment and may be a barrier to corroborating findings on standard-
ized assessments with caregiver report [102].
1.1.6. Existing case definitions for NDD
Case definitions of neurodevelopmental delay are provided by
the World Health Organization (WHO) and the American Psychi-
atric Association (APA). Each proposes unique, but related termi-
nology to capture and define NDD.
The International Statistical Classification of Diseases and Related
Health Problems (ICD) is the medical classification system of the
WorldHealth Organization (WHO). Impairment or delay in themat-
uration of the brain and central nervous system is underscored by
Table 1
Causes of neurodevelopmental delay.
Condition Category Examples
Perinatal and neonatal events [53]  Maternal factors [54,55] (hypothyroxinemia, gestational diabetes)
 Premature birth [56] (brain volume changes, white matter injury, intraventricular hemorrhage, IUGR, chronic lung disease)
 Low, very low, or extremely low birth weight [57]
 Intrauterine growth restriction [58]
 Intra-partum related brain injury [59] (hypoxic-ischemic encephalopathy, hemorrhage, perinatal arterial ischemic stroke)
 In-utero and Neonatal infections [60] (e.g., Zika [61], Rubella, Varicella zoster, CMV, GBS, E. coli, Listeria, etc)
 Increased unbound bilirubin levels [62]
 Neonatal hypoglycemia
 Exposure to maternal toxins [63] (e.g., fetal alcohol syndrome, narcotics, opioids)
 Disorders of neuronal migration [15]
Post-neonatal infections  HIV infection [64,65]
 Tuberculosis (TB) [66] (Meningitis, tuberculomas, post infection hydrocephalus)
 CNS infections [67] (Viral, bacterial : Meningitis, meningoencephalitis, encephalitis, brain abscess)
 Post-infectious sequelae (e.g. Sub-acute sclerosing pan-encephalitis, vasculitis)
 Malaria [68] (e.g. cerebral or severe systemic malaria complicated by seizures)
 Parasitic infection [69] (e.g. neurocysticercosis)
Neurological disorders  Congenital (Neuronal migration disorders, neural tube defects, hydrocephalus)
 Acquired (Stroke, vasculitis)
Genetic abnormalities/syndromes  Down syndrome
 Syndromic and non-syndromic X-linked disorders (e.g. Fragile X syndrome, adrenoleukodystrophy, Rett syndrome)
 Autism spectrum disorder
 Prader-Willi syndrome
 Velocardiofacial syndrome
 Neurodegenerative diseases (e.g., sphingolipidoses, neuronal ceroid lipofuscinosis, sialidosis, etc.)
Other Congenital Abnormalities  Congenital heart disease [70]
 Congenital hypothyroidism (untreated) [71]
Inborn errors of metabolism  Disorders of glycosylation
 Disorders of cholesterol metabolism (e.g., Smith-Lemli Opitz)
 Disorders of creatinine metabolism
 Glycogen storage disorders
 Organic acid disorders
 Lysosomal storage disorders
 Mitochondrial disorders
Other childhood diseases  Epilepsy [70]
 Acquired hypothyroidism [71]
Nutritional abnormalities [46,72–74]  Malnutrition [19,47]
 Micronutrient deficiencies [75]
Toxin exposures [75–77]  Lead, mercury, organophosphate poisoning
Other medical  Repeated early childhood anesthesia/surgery [78]
 Cardiac and non-cardiac surgery [79,80]
 Post neurological trauma
Other environmental  Poverty [19,46,47,75]
 Reduced access to clean water [75]
 Maternal depression [46,75]
 Insufficient cognitive stimulation [47,75]
 Trauma and exposure to adverse experiences [75,81]
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opmental problems under the category of Mental, Behavioral and
Neurodevelopmental Disorders and the subcategory of Pervasive
and Specific Developmental Disorders. These diagnostic categories
include Specific Developmental Disorders of Speech and Language,
SpecificDevelopmental Disorder ofMotor Functioning, Other Disor-
der of Psychological Development, and Unspecified Disorder of Psy-
chological Development. Lack of Expected Normal Physiological
Development, Lack of Expected Normal Physiological Development,
Unspecified, and Delayed Milestone (for walking and talking) are
terms used in ICD-10 to capture general or specific developmental
delays [103]. The proposed11th revisiondefines neurodevelopmen-
tal disorders as behavioral and cognitive conditions that emerge
during the developmental period with difficulty in the acquisition
and execution in specific intellectual, motor, and social domains.
The proposed ICD-11 continues to use the term ‘‘delayedmilestone”
to capture delays in social, motor and language domains.
The American Psychiatric Association (APA)’s Diagnostic and
Statistical Manual of Mental Disorders, 5th Edition (DSM-5) was
developed with the goal of harmonization with ICD-11. NDD is
addressed in several diagnostic categories. Global Developmental
Delay (GDD) is a broader diagnostic description that defines
individuals under the age of 5 who fail to achieve developmentalmilestones in two or more developmental domains at the expected
age. A diagnosis of GDD can also be given when global develop-
mental delays are observed, but the child is either too young or
unable to undergo systematic testing [104]. Delays in specific
domains of language and motor are addressed through the diag-
nostic categories of Communication Disorders (e.g., Language
Disorder) and Motor Disorders (e.g., Developmental Coordination
Disorder), respectively. Diagnoses of Other Specified Neurodevel-
opmental Disorder and Other Unspecified Neurodevelopmental
Disorder are applied when a NDD is present with an observed
impairment in functioning, but the child does not meet criteria
or there is not sufficient information for a more specific diagnosis
of NDD. [104].
There are some differences among the two major classification
systems in the lexicon of the diagnosis of NDD. However, there is
substantial overlap regarding the inclusion of different develop-
mental domains and the shared view that these conditions arise
during the early developmental period and impact functioning of
the child in daily life.
1.1.7. Need for a harmonized definition of NDD
There is no uniformly accepted definition of NDD that can be
applied to evaluate outcomes following immunizations in preg-
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trials or surveillance systems would facilitate data interpretation
and promote the scientific understanding of NDD in the context
of the assessment of safety of vaccines for maternal
immunization.
In this paper, we provide a case definition for NDD, which
focuses on a child’s performance in specific domains. This defini-
tion is distinct from neurodevelopmental disorder diagnoses, such
as autism, intellectual disability, attention deficit/hyperactivity
disorder; medical diagnoses such as cerebral palsy, HIV or specific
genetic syndromes; or hearing, vision, or other sensory impair-
ments. Diagnosis of these disorders typically requires a specialized
clinical skill set or medical tests. However, presumably, many chil-
dren with these diagnoses would also meet criteria for a NDD
based on the current case definition.
1.2. Methods for the development of the case definition and guidelines
for data collection, analysis, and presentation for NDD as an adverse
event following maternal immunization
Following the process described in the overview paper
[105] as well as on the Brighton Collaboration Website
http://www.brightoncollaboration.org/internet/en/index/process.
html, the Brighton Collaboration Neurodevelopmental Delay
Working Group was formed in 2018 and included members of clin-
ical, academic, public health, and industry background with varied
geographic representation. The composition of the working and
reference group as well as results of the web-based survey com-
pleted by the reference group with subsequent discussions in the
working group can be viewed at: http://www.brightoncollabora-
tion.org/internet/en/index/working_groups.html.
To guide the decision-making for the case definition and guideli-
nes, a literature search was performed using Medline, PubMed,
Embase, Cochrane Libraries, Ovid, Springerlink, and Google Scholar
including the terms ‘‘neurodevelopmental disorder”; ‘‘neurodevel-
opmental disability”; ‘‘neurodevelopmental delay”; ‘‘neurodevelop-
mental impairment”; ‘‘neurodisability”; ‘‘neurodevelopment”;
‘‘developmental delay”; ‘‘developmental disability”; ‘‘global devel-
opmental delay”; and ‘‘delayed milestones”. The search resulted in
the identification of 9394 references. A broader literature search
for articles with ‘‘neurodevelopmental delay” in the title resulted
in 147 articles. Finally, when the term ‘‘definition” was added to
terms related to NDD, the search resulted in identification of 29 ref-
erences. All titles and abstracts were reviewed to document the
existing definitions of neurodevelopmental delay and methods of
evaluation. General medical, neurodevelopmental, pediatric and
infectious disease textbooks were also searched. The methods and
results of the search to assess the existing literature on maternal
immunization and neurodevelopmental delay are described in
Section 1.2.1.
Findings from the literature search included a wide range of
case reports, survey research, and cross-sectional and longitudinal
studies. The terminology for neurodevelopmental delay was incon-
sistent across studies. There was also a large range in what
constituted a ‘‘delay” across studies. In many studies NDD was
defined by delays in one or more developmental domains (e.g.,
motor, language). Some studies used the term ‘‘developmental
delay” and did not provide a case definition. As a result, the work-
group members reviewed 3 case definitions (i.e., ICD-10, ICD-11,
DSM-5) in addition to considering common definitions used in
research.
1.2.1. NDD following maternal immunization
In order to identify any reported potential association of mater-
nal immunization with infant neurodevelopmental delay (NDD),separate literature searches were performed using Medline,
PubMed, the Cochrane libraries, and Embase.com. The results were
limited to those in the English language and published in the last
10 years in Embase, while no time or language limits were
selected for the other searches. All searches included the terms
‘neurodevelopmental delay,’ ‘developmental delay,’ ‘maternal
immunization,’ ‘maternal vaccination,’ ‘pregnancy vaccination,’
‘antenatal, ‘vaccine’ in conjunction with a specific vaccine, includ-
ing tetanus (TT, Td, Tdap), pertussis (Tdap), seasonal or pandemic
influenza, hepatitis (any), meningococcal, measles, mumps,
rubella, MMR, varicella, yellow fever, group B streptococcus
(GBS), and respiratory syncytial virus (RSV). These terms were
either present as subject headings or in the title or abstracts.
The Medline, PubMed, and Cochrane searches jointly yielded a
total of 132 publications. All titles and abstracts were screened
for possible reports of NDD followingmaternal immunization.Most
publications referred to the effect of infection in pregnancy on the
infant’s development (e.g., maternal rubella, cytomegalovirus
(CMV), hepatitis B, or HIV infections), infections in the perinatal
period and neurodevelopment (e.g., Group B streptococcus (GBS)
infections), or were evaluating the effect of mercury or thimerosal
exposures during pregnancy or during childhood vaccination.
Among the results, 5 articles with potentially relevant material
were reviewed in detail and summarized in a report including
information on the study type, the vaccine, the diagnostic criteria
or case definition used, and the clinical description of the cases.
Of these, one observational study of tetanus vaccine exposure
(Td) did not find an association between maternal immunization
and neurodevelopmental delay in their children [106,107]. One
study, focusing on understanding thimerosal exposure from Td
vaccine during pregnancy, defined neurodevelopmental delay by
using parameters set by the Gesell Developmental Schedules
(GDS), which included reflexes, postural reactions, and measures
of motor, visual, and auditory development and reactions in
response to stimuli, and evaluated exclusively breastfed infants
of mothers who received 1–3 doses of Td vaccine. The study con-
cluded that maternal thimerosal exposure in Td vaccines per se
was not associated with neurodevelopmental delays measured
by GDS in infants at 6 months of age. In one recent study, neither
influenza nor Tdap vaccination during pregnancy was associated
with increased risk for ASD in infants of vaccinated mothers
[107]. In addition, five Cochrane meta-analyses of various vaccines
administered during pregnancy, including Haemophilus influenza
type b, influenza, pneumococcal vaccine, Hepatitis vaccine and
tetanus vaccine, did not identify neurodevelopmental issues in
infants of vaccinated mothers, although testing tools were not
described [108–112].
The Embase platform search resulted in 96 references overall.
All titles and abstracts were reviewed for possible reports of NDD
following maternal immunization. Publications in which the NDD
discussed in the article was a result of an infection or another
known condition and vaccines were only mentioned tangentially,
or developmental delay was not actually discussed in the study,
were eliminated. A total of 34 articles were identified and reviewed
in more detail. Nine book chapters that focused on neurodevelop-
ment or neurodevelopmental disorders were also reviewed. Simi-
lar to the prior searches, most publications were evaluating the
safety of vaccines in children, not pregnant women, including the
effect of vaccine components, such as thimerosal and aluminum
in neurodevelopment.
Only 3 articles provided information on vaccines administered
during pregnancy. Among these, the same article of Td vaccination
in pregnancy described above [106] was identified. The second
article was a systematic review of maternal immunization which
searched available safety evidence in PubMed and Scopus data-
bases, as well as post-marketing surveillance data, including the
Table 2
Neurodevelopmental domains included in the NDD case definition.
Domain Definition Commonly Used Terms
Motor Gross-motor skills: large,
coordinated body
movements (e.g., crawling,
walking); Fine-motor skills:
small, precise hand
movements (e.g., picking
something up with hands,
using an eating utensil)
Movement, physical
development, fine-
motor skills, gross-
motor skills
Language Expressive language: ability
to express interests,
thoughts, needs; Receptive
language: ability to
understand what others say
Communication, speech,
expressive language,
receptive language
Cognitive/Problem
Solving
Capacity to learn, reason and
think in order to solve a
problem, explore and play
Thinking, learning,
reasoning, visual-
reception, non-verbal
reasoning
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review identified 6 studies on hepatitis B vaccine, 6 on pneumococ-
cal polysaccharide vaccine (PPSV23), and 3 on meningococcal
polysaccharide vaccine (MPSV), plus 3 additional studies that com-
pared PPSV with MPSV in pregnant women [113]. Additionally, the
study included 91 reports on vaccinations in pregnant women
identified from post-marketing surveillance data (88 on hepatitis
B, 2 on PPSV, and 1 on MPSV). Overall, NDD in infants of vaccinated
mothers was not reported as an event in this systematic review.
The third article was a systematic review of the safety of influenza
immunization during pregnancy for the fetus and neonate, which
summarized 40 years of research on influenza vaccination in preg-
nant women, and did not identify infant developmental delay as a
concern [114].
Recent clinical studies of influenza, Tdap, RSV and GBS vaccines
administered during pregnancy have included neurodevelopmen-
tal evaluation of infants for a variable period of time, usually 6
months to the second year of life, using various tools such as the
Bayley Scales of Infant and Toddler Development, Third Edition
[115]. No specific associations between maternal vaccination and
neurodevelopmental deficits have been identified in these studies
[116–124].
In summary, no evidence of an association between vaccination
during pregnancy and NDD in infants and young children was
found.
1.3. Rationale for selected decisions about the case definition of NDD as
an adverse event following maternal immunization
The focus of the working group was to agree on a harmonized
definition of NDD and how to identify it with different levels of cer-
tainty, which will be useful for the identification of NDD in the con-
text of vaccination of women during pregnancy.
The working group agreed that the term NDD describes a group
of developmental problems that begin during the early develop-
mental period and result from impairment in the central nervous
system. NDD manifests as developmental functioning that is at
least two standard deviations below the norm in one or more of
the following domains: gross motor, fine motor, expressive lan-
guage, receptive language, and/or cognitive/problem-solving.
Levels of diagnostic certainty are suggested by the working
group based on two major considerations: 1) the background,
training and ability of the evaluator to ascertain the presence of
NDD and 2) the methods/tools utilized for assessment (see Sec-
tions 1.3.6 and 1.3.7). The diagnostic levels of certainty should be
applied separately to each domain evaluated. The diagnostic levels
must not be misunderstood as reflecting different grades of clinical
severity. They instead reflect diagnostic certainty (see
Section 1.3.8).
1.3.1. Related term(s) of NDD
Related terms that are commonly used to refer to NDD include
global developmental delay, developmental delay, delayed mile-
stones, developmental disability, intellectual disability, neurode-
velopmental disability, and neurodevelopmental disorder.
Specific delays or disorders in the motor, language, and cognitive
are also used (e.g., expressive language delay, gross motor delay).
1.3.2. Domains of neurodevelopmental delay and differentiation from
other disorders
A comprehensive neurodevelopmental assessment includes all
of the domains, or developmental skill areas necessary to assess
the functioning of the child at each phase of development, includ-
ing early and late infancy, toddlerhood, and early childhood (pre-
school years). Each skill area has a trajectory of its own and is
also influenced by skill development in other areas. The sequenceof development in a specific domain is near universal in most cases
(e.g., babbling followed by first words), but the rate of skill devel-
opment in each area may differ. A child may advance within typical
timeframes for one domain while lagging behind in another
domain at a given age (i.e., dissociation of skills). Therefore, it is
imperative to assess for neurodevelopmental delay comprehen-
sively and document if a child is meeting developmental mile-
stones for each specific domain across time points.
For the current case definition, the neurodevelopmental
domains of gross motor, fine motor, expressive language, receptive
language, and cognitive/problem solving are considered in children
0–5 years of age (see Table 2). The recommended domains corre-
spond not only to the developmental areas outlined in the ICD-
10 and ICD-11 definitions of Delayed Milestones [103], but also
to the selected domains evaluated on standardized measures of
development [125–128].
There are additional domains that should be considered in the
context of a comprehensive neurodevelopmental assessment, but
for which an isolated problem does not meet criteria for the cur-
rent case definition. These include social, emotional, and behav-
ioral adjustment, as well as daily living skills (also referred to as
adaptive behavior). The rationale behind these decisions is
explained briefly next.
Age appropriate social, emotional, and behavioral adjustment is
dependent on healthy brain development, and a NDD can manifest
as difficulties in one or more of these areas. However, for the pur-
pose of the present case definition, we do not recognize an isolated
problem in social, emotional, or behavioral functioning for multi-
ple reasons. In this age range, social, emotional, and behavioral
functioning are measured primarily with caregiver-report ques-
tionnaires. Results can therefore be heavily influenced by contex-
tual factors, including varying cultural expectations, as well as
caregiver literacy and comprehension. Practically speaking, exist-
ing measures vary widely in the specific skills they assess making
global comparisons difficult, and access to well-validated and
locally-adapted measures is a barrier in many settings around
the world. In the future, as researchers further define the specific
social, emotional, and behavioral subskills most likely to result
from atypical neurodevelopment in infants and young children
and as more reliable and valid measures of those skills become
available globally, it could become more appropriate to recognize
a single-domain problem in one of these areas as meeting criteria
for NDD. For now, clinicians and researchers should at least screen
for concerns in these areas whenever possible for two reasons.
First, results can provide important information about the validity
of other assessment measures. For example, a child who is highly
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ment of cognition or language. Second, concerns about social, emo-
tional, or behavioral functioning will often drive clinical
management, including intervention recommendations.
Daily living skills (adaptive behavior) are also primarily mea-
sured by caregiver questionnaire or interview, and so reliable
assessment of this domain is also dependent on the literacy or
comprehension of the caregiver. Furthermore, delays in this
domain are not typically seen in isolation. Rather delays in daily
living skills are usually the result of a delay in another of the out-
lined neurodevelopmental domains (cognitive, motor, language)
and therefore, are not included in the current case definition.
1.3.3. Duration of follow up and age range of neurodevelopmental
delay
There are no standard minimum or maximum duration of fol-
low up requirements in studies of maternal immunization [129].
However, in order to determine there has been no adverse devel-
opmental outcome and a case of neurodevelopmental delay is
not present or does not arise during the period of early childhood,
it is recommended that assessment occur in each of the following
four time periods: early infancy (0–6 months), late infancy (7–18
months), toddlerhood (19–36 months) and preschool years (37–
60 months). While a single time point may be adequate and
acceptable for some studies, the strength of any given study will
improve with each additional time point added. Additionally, if a
single time point is the only available option, choosing which of
the four time periods in which to conduct the assessment should
be determined by the aims of the study.
When feasible, assessment at multiple time points throughout
the period of early childhood is important for several reasons
[130–132]. First, even the most robust, standardized developmen-
tal assessments have psychometric limitations at the youngest
ages [133]. These include floor effects (i.e., infants have a limited
repertoire of skills and therefore the number of test items for
younger children is limited), and limitations of test/retest reliabil-
ity and sensitivity/specificity [133]. Neurodevelopmental re-evalu-
ations over time can improve the ability to detect a NDD and
prognosticate long-term outcomes [8]. Second, as previously sta-
ted, developmental skill attainment can be variable, such that
delays may spontaneously resolve, remit following intervention,
or worsen as environmental demands increase and a child fails
to acquire the necessary skills to meet these demands [134–137].
1.3.4. Influence of treatment on fulfillment of case definition
The Working Group decided against using ‘‘treatment” or
‘‘treatment response” towards fulfillment of the NDD case defini-
tion. A treatment response or its failure is not in itself diagnostic,
and may depend on variables like clinical status, time to treatment,
availability of treatment and other clinical parameters.
1.3.5. Timing post-maternal immunization
A definition designed to be a suitable tool for the eventual
assessment of causal relationships requires ascertainment of the
outcome (e.g., neurodevelopmental delay) independent from the
exposure (e.g., maternal immunizations). Therefore, to avoid selec-
tion bias, a restrictive time interval from maternal immunization
to onset of neurodevelopmental delay should not be an integral
part of such a definition. Instead, where feasible, details of this
interval should be assessed and reported as described in the data
collection guidelines.
Further, unlike other medical events, there is typically not a
sudden onset of a NDD and delays arise outside the controlled set-
ting of a clinical trial or hospital. In some settings, it may be impos-
sible to obtain a clear timeline of the event, particularly in lessdeveloped or rural settings. In order to avoid selecting against such
cases, this case definition avoids setting arbitrary time frames.
To determine that a case of NDD is present or arises during the
period of early childhood, best practice would include continued
assessment over the four time periods (early infancy, late infancy,
toddlerhood, preschool years), as outlined in Section 1.3.3. How-
ever, there are no standard minimum or total duration of follow
up requirements in studies of maternal immunization. Therefore,
the minimum and total duration of assessment for NDD must be
determined for each study, based on the specific needs and charac-
teristics of the study, including the vaccine, the study population,
and other relevant factors.
A study with a limited timeframe (i.e., including less than the
four suggested time periods) will not limit the researcher’s ability
to obtain Level 1 diagnostic certainty. However, it will limit the
researcher’s opportunity to identify all potential cases of NDD that
may have arisen in the time of early childhood and may have been
captured at other time points. Importantly, a case of NDD that is
identified at an early time point (e.g., late infancy) and is no longer
identified at a later time point (e.g., preschool years) should be
considered a documented case of NDD (at the appropriate level
of certainty for the early time point) and not as a false positive
because delays can spontaneously resolve or respond to treat-
ment/intervention.
1.3.6. Defining the ‘‘Gold Standard” – Personnel
This section describes characteristics of gold standard personnel
for assessment of NDD. The diagnosis of a NDD is based on observ-
able behavior in the child and requires more subjective judgement
than a standard medical test or the developmental assessment of
older children, which may provide more objective results. There-
fore, diagnostic certainty for a diagnosis of NDD must rely more
heavily on the training and background of the evaluator. Gold stan-
dard personnel have the training and expertise to select, adminis-
ter, score, and interpret the measures described below. In general,
such professionals will have the highest available level of training
in assessment of children aged 0–5 years. In HIC settings, training
will typically include a doctoral degree (i.e., physician or psychol-
ogist) with specialized training in assessment of infants and young
children (e.g., developmental pediatrician, pediatric neuropsychol-
ogist, pediatric neurologist, pediatrician or clinical psychologist
who has pursued focused training in early childhood assessment).
In LMIC settings, there will be cases where the available profes-
sional training/credentialing diverges from these examples; pro-
fessionals in those settings still meet gold standard criteria if
they have completed the highest level of training available in their
setting and specialize in the assessment of young children. A
domain-specific specialist could also meet gold standard criteria
if the delay is identified within that single domain. Thus, a
speech-language therapist with appropriate training/experience
in children aged 0–5 would meet gold standard criteria for diag-
nosing NDD impacting language, while a physical or occupational
therapist with appropriate experience could meet such criteria
for diagnosing a NDD impacting motor skills. Gold standard per-
sonnel must be fluent in the native language of the child being
assessed.
If gold standard personnel are not available, diagnosis of NDD
can be made at a lower level of certainty. We discriminate two fur-
ther categories of personnel, ‘‘below gold standard” and ‘‘well
below gold standard.” A listing of the personnel belonging to each
category is provided in Table 3. In general, below gold standard
personnel include professionals with similar general background
training to gold standard personnel (e.g., physicians, psychologists,
domain-specific specialist evaluating that domain), but less com-
prehensive specialization in early childhood assessment. Nurses
and social workers with early childhood assessment training also
Table 3
Personnel standards.*
Gold standard  Diagnosis made by an evaluator fluent in the native language with advanced training and expertise in 0–5 assessment and with the highest
level of training as defined by the specific setting (e.g., HIC or LMIC).
 Diagnosis in a specific domain made by a specialist in that domain (e.g., a speech/language therapist). This specialist should have advanced
training and expertise in 0–5 assessment and have the highest level of training as defined by the specific setting.
Below gold standard  Diagnosis made by an evaluator with advanced training and the highest level of training as defined by the specific setting, but without or
less expertise in 0–5 assessment.
 Domain specific specialist as defined by the setting (e.g., a speech/language therapist) for each domain assessed without or less expertise in
0–5 assessment.
 Nurse or equivalent health care provider, as defined by the highest level of training for the specific setting, with expertise in 0–5 assessment.
 Domain specific specialist as defined by the setting with expertise in broad-based 0–5 assessment, or assessment of skills outside of the area
of primary expertise (e.g., a speech/language therapist evaluates motor and cognitive functioning).
Well below gold
standard
 Diagnosis made by a trained provider or community health worker with at least minimal training in 0–5 neurodevelopmental assessment.
* For the purpose of research studies, personnel can move up one level from the level at which they are placed by their training and background (i.e., from well below gold
standard to below gold standard or from below gold standard to gold standard) if they are administering a specific measure on which they have been adequately trained by
gold standard personnel.
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community health workers or the equivalent who lack expertise
or have only limited training in child development, psychometrics,
and the assessment process.
For the purpose of research studies, personnel can move up one
level from the level at which they are placed by their training and
background (i.e., from well below gold standard to below gold
standard or from below gold standard to gold standard) if they
are administering a specific measure on which they have been ade-
quately trained by gold standard personnel. In these cases, it is use-
ful to periodically and formally measure the accuracy and
reliability of the trainee (i.e., through interrater reliability, rater
accuracy) to ensure they have achieved and have retained mastery
of that particular measure.
Additionally, if an interpreter is used, that interpreter should be
professional/certified or properly trained as a translator as defined
by the setting. When an interpreter is used for the assessment of
motor skills, the LOC is determined by the qualifications of the pri-
mary evaluator because the primary evaluator is still able to
observe and evaluate the child’s performance first hand. However,
when an interpreter is used for language and/or cognitive assess-
ment, the LOC moves down one level from the level defined by
the qualifications of the primary evaluator. In these cases, the eval-
uator must rely on the interpreter to translate the child’s responses
and so direct assessment by the evaluator of the child is not possi-
ble. The assessment measure should also already be in the target
language and ‘‘live interpretation,” or translation of a testing mea-
sure during the assessment, is not recommended. The use of family
members for interpretation is also not recommended.1.3.7. Defining the ‘‘Gold Standard” – Assessment
The goal of this section is to describe characteristics of a gold
standard assessment tool for NDD in children aged 0–5 years. By
‘‘gold standard” we do not mean a perfect assessment, but simply
the best that is currently available [138]. In clinical practice, diag-
nosis should result from a process through which a competent pro-
fessional integrates test results assessing neurodevelopmental
domains with information about the child’s history (typically
gleaned from caregiver interviews and any available medical
records) and current functioning (gleaned from interviews, obser-
vations, and/or caregiver-completed rating scales) [139]. When
classifying children for research purposes, the process is similar
but will de-emphasize clinical judgment and rely more heavily
on specific test scores. Nonetheless, involvement of appropriately
trained personnel is important to ensure proper test administra-
tion, scoring, and interpretation (see Section 1.3.6).Robust standardized tests are a pillar of gold standard assess-
ment for NDD. A discussion of specific measures is beyond the
scope of this paper; fortunately, several relevant reviews have
recently been published [35,140,141]. Whenever possible, mea-
sures should provide coverage of the five neurodevelopmental
domains identified earlier (gross and fine motor, expressive and
receptive language, and cognition/problem solving). In almost all
cases, these are best assessed with standardized performance-
based assessments that are individually administered to the child.
Multiple measures are sometimes needed, although some infant
and young child assessments encompass all domains [115,142].
Gold standard assessment measures are characterized by a
number of important features. First, they should be psychometri-
cally robust with evidence for good reliability, validity, and sensi-
tivity/specificity for the population and context in which they are
being used [93]. Reliability encompasses measures of internal con-
sistency, test–retest stability, and inter-rater agreement. General
guidelines [143] suggest that for measures of internal consistency
(e.g., Cronbach’s alpha) and test–retest stability (e.g., Person’s r),
values > 0.7 indicate adequate reliability while values > 0.85 are
preferable. For measures of inter-rater agreement (e.g., kappa), val-
ues > 0.4 are adequate while values > 0.6 are preferable. Validity is
a multi-tiered construct, only some aspects of which can be readily
captured statistically. The most straightforward way to establish
diagnostic validity of a measure is by comparison to an existing
gold standard (i.e., criterion validity), but this approach is not cur-
rently feasible in many parts of the world. Convergence with cur-
rent indicators of daily functioning or prediction of future
functioning (e.g., adaptive behavior, academic achievement, or
diagnosis of intellectual disability) can also support the validity
of neurodevelopmental measures. Sensitivity is the test’s ability
to correctly identify patients with NDD, while specificity is the
test’s ability to correctly identify those without NDD. Diagnostic
assessment should maximize both sensitivity and specificity, with
levels of 70–80% or greater generally considered acceptable [144].
An additional psychometric consideration for assessment of NDD
in young children is that the measure must include enough easy
items to capture variability in the low tail of the distribution (i.e.,
avoid a floor effect).
A second characteristic of gold standard measures is that they
must be linguistically and culturally appropriate for the child and
family. Since the most widely used standardized measures have
been developed and researched in HICs and originally written in
English, assessment of children in LMICs and non-English speaking
countries often requires translation and adaptation of existing
measures. There is a literature to support using tests developed
in HICs to assess children in LMICs when carefully, translated,
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ensure they are culturally and linguistically appropriate
[149–151]. Of course, the psychometrics of an adapted test need
to be studied and the LOC will be determined by the outcome of
those studies (with consideration for the expertise of personnel)
and not by the psychometrics of the original version of the test.
Therefore, while certainly complex and requiring careful consider-
ation of norming and these other issues, it is possible to attain a
high level of diagnostic certainty with an adapted test. Another
option available is the creation of a new test. Both adapta-
tion/translation and new test development are complex and chal-
lenging and readers are referred elsewhere for a detailed
description of the issues involved [140,152,153].
Third, gold standard tests must have appropriate norms avail-
able, which means that the demographic characteristics of the
child being evaluated should be represented in the normative sam-
ple. National or regional norms are often preferable [154]. Narrow
norms (e.g., drawn from a small local population) are often insuffi-
cient for diagnosis of NDD generally as they may obscure the
effects of true etiologic risk factors that have negatively impacted
a large proportion of children in a locale (e.g., disease, malnutrition,
psychosocial adversity, etc.). However, when attempting to isolate
the potential effect of maternal vaccination, local norms may be
appropriate by controlling for other neurodevelopmental risk fac-
tors common to children in that community. Determining which
measures are the best available will also rely on practical consider-
ations, such as affordability and access to an appropriate testing
environment. In general, measures should be appealing to infants
and young children who may have limited experience interacting
with strangers and should also be robust to minor fluctuations in
the child’s physical/emotional state.
In some circumstances, the only available measure will be a
universal or regional developmental milestones checklist. This is
not ideal as the psychometric properties of a developmental mile-
stones checklist utilized to diagnose NDD are unknown and are
likely substantially weaker than for standardized performance-
based testing. Additionally, the demographics of representative
children may be too broad to apply to an individual child. However,
if a checklist is the only option and is utilized, NDD is diagnosed at
a low level of certainty (well below gold standard assessment with
consideration for the expertise of the evaluator determining the
level), regardless of the severity of NDD identified.
In addition to selecting measures with demonstrated validity at
the group level, the examiner must consider factors that can pro-
vide a threat to the validity of an individual test administration.Table 4
Assessment standards.*
Gold standard Performance that is 2.0 or more standard deviations below the
has strong psychometric properties defined for each domain.
 Strong reliability (i.e., internal consistency and test–retes
 Strong evidence for validity in the context in which is it b
appropriate; correlates around 0.8 or higher with existing
measures of adaptive functioning)
 Sensitivity and specificity > 0.7–0.8
 Test has norms available with the demographic character
Below gold standard Performance that is 2.0 or more standard deviations below the
cultural and linguistic appropriateness and/or has suboptima
 Adequate reliability (i.e., internal consistency or test–rete
 Some evidence for validity in the context in which it is b
 Sensitivity or specificity values < 0.7
 Appropriate norms are not available
Well below gold
standard
Performance that is 2.0 or more standard deviations below th
appropriateness and psychometrics defined for each domain.
 Inadequate reliability, little evidence for validity in the co
 Norms do not include demographic characteristics of the
When using a universal or regional developmental milestones checklist, NDD is diagnose
month delay or more for a child 12 months of age) is found when measured against a uIn other words, if a child obtains a low score, it should be because
of true neurodevelopmental problems rather than uncorrected
sensory impairments, inhibited temperament, fatigue, lack of
familiarity with test materials/expectations, or other such factors
[140]. Personnel with expertise in early childhood assessment
should be able to ensure that the child is calm, alert, and engaged
before proceeding with standardized testing. In older children,
standardized measures are available to objectively assess test
engagement [155], but in infants and very young children, clinician
judgment is required. Caregiver interview should be conducted to
help establish that scores from tests individually administered to
the child are valid (i.e., reflective of the child’s typical daily func-
tioning). The evaluator should always include screening for hearing
and vision problems (i.e., by asking whether the child has had
recent vision/hearing tests, asking caregivers about vision/hearing
concerns, and using behavioral observations to gauge whether
vision or hearing difficulties appear to interfere with testing).
Please refer to the Section 1.3.9 for more detailed information.
The general principles characterizing gold standard assessment
of NDD are universal, but the most appropriate specific measures
will depend on multiple factors and in many contexts, there will
be barriers to an optimal assessment process. If gold standard mea-
sures are not available, a diagnosis of NDD can be made at a lower
level of certainty (i.e., ‘‘below gold standard” and ‘‘well below gold
standard”). A listing of the assessment standards belonging to each
category is provided in Table 4.1.3.8. Formulating a case definition that reflects diagnostic certainty:
weighing specificity versus sensitivity
It needs to be re-emphasized that the grading of definition
levels is entirely focused on diagnostic certainty, not the clinical
severity of a NDD. Thus, a clinically very severe NDDmay appropri-
ately be classified as Level 2 or Level 3 if Level 1 personnel and
procedures were not available. Detailed information about the
severity of the event should additionally always be recorded, as
specified by the data collection guidelines below.
The number of symptoms and/or signs documented for each
case may vary considerably. The case definition has been formu-
lated such that the Level 1 definition aims to be as specific as pos-
sible for the condition. As maximum specificity normally implies a
loss of sensitivity, three diagnostic levels have been included in the
definition, offering a stepwise attempt to increase sensitivity from
Level 1 down to Level 3, while aiming to retain acceptable speci-
ficity at all levels.mean with a test/instrument that is culturally and linguistically appropriate and
For example:
t > 0.85; interrater agreement > 0.6)
eing used (e.g., local content experts agree items are culturally and linguistically
gold standard measure or correlates around 0.8 or higher with current or future
istics of the child being assessed represented in the norming sample
mean with a test/instrument that does not meet the gold standard threshold for
l psychometric properties defined for each domain. For example:
st > 0.7 but  0.85, interrater agreement > 0.4 but  0.6)
eing used, but does not meet gold standard criteria
e mean with a test/instrument that is well below threshold cultural/linguistic
For example:
ntext in which the is being used, or sensitivity and specificity well below < 0.7
child being assessed
d when a minimum delay equal to or greater than half of the child’s age (e.g., a six
niversal or regional developmental milestones checklist.
Confirmed by behavioral observations of child by the clinician and 
caregiver interview.
AND
The evaluator has determined that the reported delay in a specific domain
is not caused by a specific sensory impairment (e.g., hearing or vision)
and that motor impairment did not disrupt performance on non-motor
tasks 
AND
The evaluator has determined that the infant or child’s arousal and
attentional state were appropriate for adequate test engagement and did
not interfere with the assessment.   
Level 1. Diagnostic certainty.
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When the gestational age of a child is known, most tests require
than an age correction is made to account for preterm birth. That is,
the child is compared to children of the same chronological age
minus the number of weeks born preterm. Guidelines for age cor-
rections for prematurity are determined by the specific test being
used and are generally made until 24 months of age. There is little
empirical support for designating the appropriate length of time
for which age corrections should be made and evaluators should
abide by the guidelines set forth in the specific assessment being
used [156].
Very often, the gestational age of a child is not known. In these
cases, birth weight (if known or can be estimated) can often be
used as a proxy for preterm birth utilizing a country-wide or regio-
nal data chart. However, in LMICs there are high rates of full-term,
small for gestational age (SGA) babies born which may overesti-
mate rates of preterm birth if these charts are used in isolation
[157]. In these cases, the best available estimate should be used.
The GAIA-Brighton Collaboration case definitions and LOC for pre-
term birth and SGA could be used as reference [158,159].1.3.10. Consideration of sensory and motor impairments
Sensory (hearing or vision) and motor impairment do not pre-
clude a diagnosis of NDD. In fact, they commonly co-occur with
NDD given that the etiology of a sensory and/or motor impairment
can also be the etiology of NDD (e.g., perinatal insult that results in
visual impairment and cognitive delays). Additionally, significant
sensory and motor impairments can also serve to limit a child’s
ability to interact with the world around them, explore, and learn,
further increasing the risk of development of NDD.Among infants that survive prenatal, perinatal, or neonatal
insult, approximately 18% have visual impairment, 20% have hear-
ing impairment, and 17% have motor impairment [160]. Existing
research highlights the complex interplay between visual impair-
ment and early development [161–163]. Although there is individ-
ual variation in outcomes, studies identify between 21% and 71%
comorbidity between visual impairment and developmental,
learning, and medical problems [164]. Hearing impairment is also
often related to cognitive functioning, with many etiologies of
hearing loss related to risk for lower intelligence [165]. With
regard to physical impairments, early motor delays often indicate
broader neurological dysfunction [166], and there is a high rate
of comorbidity between motor deficits and other NDD [167].
Despite the increased risk of NDD in these populations, children
with known sensory or motor impairments are often excluded
from the standardization samples of established developmental
measures [168], and routine assessment of children with these
impairments is not conducted in many countries [169]. Moreover,
administration procedures for standardized developmental assess-
ments are designed and established for children without these
impairments. As a result there are often limited accommodations
for children when these impairments are present [170].
Consideration of a sensory or motor impairment is always an
essential part of a comprehensive neurodevelopmental assessment
because NDD may be a clinical manifestation of a pathology also
manifesting with sensory or motor impairments. Inquiring as to
caregiver concerns for hearing, vision, or motor impairments and
asking specific questions about sensory and motor behaviors is a
critical aspect of evaluating for such problems early in develop-
ment. Brief, behavioral screenings appropriate for the child’s age
are conducted to assess the potential impact that limitations in
Confirmed by behavioral observations of the child by the clinician and 
caregiver interview.
AND
AND
The evaluator has determined that the infant or child’s arousal and 
attentional state were appropriate for adequate test engagement and
did not interfere with the assessment.   
The evaluator has determined that the reported delay in a specific
domain is not caused by a specific sensory impairment (e.g., hearing
or vision) and that motor impairment did not disrupt performance on
non-motor tasks.   
Level 2. Diagnostic certainty.
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ing can be screened by observing behavioral responses to items on
neurodevelopmental measures, such as response to novel sounds
without visual input, response to commands or instructions, and
response to questions. Vision can be screened by observing the
child’s ability to fixate on, track, and localize objects, respond to
items at a desktop distance, imitate visually presented behavior,
complete puzzles, and match or sort objects. Motor skills screen-
ing, to ensure that a child has adequate motor skills to complete
non-motor tasks, can include observing the child’s ability to hold,
grasp, or reach for an object, maintain a sitting posture and head
control, and point proximally. If concerns about a child’s hearing,
vision, or motor skills arise, referral for a medical examination is
warranted in addition to more in-depth hearing, vision, or motor
examination. Additional information about medical examinations
related to these concerns is beyond the scope of this paper.
Some test manuals provide possible accommodations for test-
ing that do not alter test validity [115,171]. Although for the major-
ity of tests, research is lacking on the influence of adaptations of
test administration on results [172]. Even when test manuals do
not provide this guidance, an evaluator with expertise in 0–5assessment may be able to make adaptations based on clinical
judgment and experience and interpret the results meaningfully.
For example, some subtests can be administered in standard for-
mat (e.g., a child with hearing impairment may be able to partici-
pate in motor assessment) and others can be adapted to minimize
the impact of the sensory impairment (e.g., stimuli can be placed in
the hand of a child with motor impairment to elicit exploration
versus expecting the child to reach and grab). It may be deter-
mined that some tests cannot be administered validly due to the
specific impairment (e.g., a child with visual impairment may not
be able to engage in gross motor tasks, such as running or climbing
stairs). An experienced evaluator is able to interpret test results
with consideration of the sensory or motor impairment and the
impact of any deviation from standardized administration.
1.4. Guidelines for data collection, analysis and presentation
The case definition is accompanied by guidelines that are struc-
tured according to the steps of conducting a clinical trial, i.e., data
collection, analysis and presentation. Neither case definition nor
guidelines are intended to guide or establish criteria for manage-
Level 3A. Diagnostic certainty.
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improve data collection and comparability.1.5. Periodic review
Similar to all Brighton Collaboration case definitions and guideli-
nes, review of the NDD case definitionwith its guidelines is planned
on a regular basis (i.e. every three to five years) or more often if
needed.2. Case definition of neurodevelopmental delay
2.1. For all levels of diagnostic certainty
Neurodevelopmental delay (NDD) is a term used to describe
developmental functioning that is well below age expectations
due to known or presumed central nervous system (CNS) dysfunc-
tion. NDD is identified during the early childhood developmental
period which encompasses infancy, toddlerhood, and early child-
For caregiver report, the evaluator is unable to determine whether 
literacy and/or comprehension issues impacted the caregiver's ability 
to complete reports accurately.
Level 3B. Diagnostic certainty.
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tion operationally defines NDD as functioning at least two standard
deviations below the norm in one or more of the following
domains: gross motor, fine motor, expressive language, receptive
language, and/or cognitive/problem-solving. The fundamental
impact of a NDD is impairment in the child’s developmental course
compared to peers of the same age [173].
While there is individual variability in ‘‘typical” neurodevel-
opment, the ‘‘normal distribution” is generally defined as the
entire distribution of a set of characteristics that occur in a given
population. For normally distributed outcomes, 68% of the popu-
lation falls within one standard deviation of the mean and is
considered to be functioning in the ‘‘average” range [8]. Again,
for a normal distribution, 96% of the population falls within
two standard deviations of the mean, with just 2% falling in each
extreme tail of the distribution (i.e., well above or well below
average). When results of developmental testing on standardized
measures reach two standard deviations or more below the
mean for age, these findings are considered significant and when
deemed reliable within the context of gold standard levels of
diagnostic certainty (LOC), correlated with higher risk and higher
likelihood of NDD.
It should be noted, a delay that is 1.5 to < 2.0 standard devia-
tions below the mean constitutes a high-risk area of concern for
NDD and merits monitoring at a minimum. In some clinical set-tings in HICs, delays in this range are often classified and treated
as NDD [174,175]. In the context of research, documentation and
on-going monitoring of this at-risk population through the use of
the LOCs is strongly recommended.
Developmental surveillance through formal assessment is
essential when a NDD has been detected. Given the variable nature
of development and the broad variance in familial and cultural tol-
erance for developmental differences, assessment by a trained pro-
fessional provides maximum certainty that a delay has not been
present or does not arise in the period of birth to 5 years of age.
Because some delays only become evident as children face increas-
ing developmental demands, repeat assessment is necessary. As a
result, we recommend that at least one assessment in each domain
occur in at least one, or when feasible, in each of the following four
time periods: early infancy (0–6 months), late infancy (7–
18 months), toddlerhood (18–36 months) and preschool years
(37–60 months).
The levels of diagnostic certainty below describe a single assess-
ment time point for each individual domain. Therefore, for exam-
ple, one could determine that a gross motor delay was or was
not present with varying levels of certainty and that an expressive
language delay was or not present with a different level of cer-
tainty during the first six months of life. The highest LOC in the
diagnosis of NDD for each domain is achieved when gold standard
personnel administer gold standard measures and assessment
Table 5
Levels of diagnostic certainty for NDD.
Personnel Assessment
Level 1
Gold standard Gold standard
Level 2
Gold standard Below gold standard
Below gold standard Gold standard
Level 3A
Below gold standard Below gold standard
Gold standard Well below gold standard
Well below gold standard Gold standard
Well below gold standard Below gold standard
Below gold standard Well below gold standard
Level 3B
Well below gold standard Well below gold standard
Level 4
Reported NDD with insufficient evidence to meet the case definition
Level 5
Not a case of NDD
2 If the reporting center is different from the vaccinating center, appropriate and
timely communication of the adverse event should occur.
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standard LOC are more likely to yield certainty of true positives
and minimize false negative findings of NDD. A decision tree is also
provided to aid in the identification of the appropriate level of
diagnostic certainty (see Appendix A).
3. Guidelines for data collection, analysis and presentation of
neurodevelopmental delay
It was the consensus of the Brighton Collaboration Neurode-
velopmental Delay Working Group to recommend the following
guidelines to enable meaningful and standardized collection,
analysis, and presentation of information about NDD. However,
implementation of all guidelines might not be possible in all set-
tings. The availability of information may vary depending upon
resources, geographical region, and whether the source of infor-
mation is a prospective clinical trial, a post-marketing surveil-
lance or epidemiological study, or an individual report of a
case of NDD. Also, these guidelines were developed by this
working group for guidance only, and are not to be considered
a mandatory requirement for data collection, analysis, or
presentation.
3.1. Data collection
These guidelines represent a desirable standard for the collec-
tion of data on NDD in infants and young children following mater-
nal immunization to allow for comparability of data, and are
recommended as an addition to data collected for the specific
study question and setting. The guidelines are not specifically
intended to guide the primary reporting of neurodevelopmental
delay to a surveillance system or study monitor, but they could
potentially be adapted for these purposes. Investigators developing
a data collection tool based on these data collection guidelines also
need to refer to the criteria in the case definition, which are not
repeated in these guidelines.
Guidelines numbered 1–42 below have been developed to
address data elements for the collection of adverse event infor-
mation as specified in general drug safety guidelines by the
International Conference on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals for Human Use, and
the form for reporting of drug adverse events by the Council
for International Organizations of Medical Sciences. These data
elements include an identifiable reporter and patient, one or
more prior maternal immunizations, and a detailed description
of the adverse event, in this case, of NDD in infants followingmaternal immunization. The additional guidelines have been
developed as guidance for the collection of additional informa-
tion to allow for a more comprehensive understanding of neu-
rodevelopmental delay in infants following maternal
immunization.3.1.1. Source of information/reporter
For all cases and/or all study participants (including mothers
and infants, as appropriate), the following information should be
recorded:
(1) Date of report.
(2) Name and contact information of person reporting2 and/or
diagnosing the neurodevelopmental delay as specified by
country-specific data protection law.
(3) Name and contact information of the investigator responsi-
ble for the participant, as applicable.
(4) Relation to the patient (e.g., clinician, nurse, family member
[indicate relationship], other).
3.1.2. Vaccine/Control
3.1.2.1. Demographics. For all cases and/or all study participants
(including mothers and infants, as appropriate), the following
information should be recorded:
(5) Case/study participant identifiers (e.g. first name initial fol-
lowed by last name initial) or code (or in accordance with
country-specific data protection laws).
(6) Date of birth, age (and corrected age to account for prematu-
rity if used), and sex.
(7) For infants: Gestational age and birth weight3.1.2.2. Clinical and immunization history. For all cases and/or all
study participants (including mothers and infants, as appropriate),
the following information should be recorded:
(8) Past and current medical and obstetric history, including
hospitalizations, underlying medical or neuropsychiatric
diseases/disorders including cases of NDD in parents, sib-
lings and/or close family members, maternal and infant
nutritional status, pre-immunization signs and symptoms
including identification of indicators for, or the absence of,
a history of allergy to vaccines, vaccine components or med-
ications; food allergy; allergic rhinitis; eczema; asthma.
Other relevant information for this outcome may include
maternal educational level, socioeconomic and environmen-
tal conditions.
(9) Any medication history (other than treatment for the event
described) prior to, during, and after maternal immuniza-
tion, including prescription and non-prescription medica-
tion as well as medication or treatment with long half-life
or long-term effect. (e.g. immunoglobulins, blood transfu-
sion and immunosuppressants), and alcohol or substance
abuse.
(10) Maternal and infant immunization history (i.e. previous
immunizations and any adverse event following immuniza-
tion (AEFI))
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For all cases and/or all study participants (including mothers
and infants, as appropriate), the following information should be
recorded:
(11) Date and time of maternal and infant immunization(s).
(12) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL, 0.5 mL, etc.) and number of dose
if part of a series of immunizations against the same disease).
(13) The anatomical sites (including left or right side) of all
immunizations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(14) Route and method of administration (e.g. intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(15) Needle length and gauge.
3.1.4. The adverse event
(16) For all cases at any level of diagnostic certainty and for
reported events with insufficient evidence, the criteria ful-
filled to meet the case definition should be recorded.
Specifically, document:
(17) Clinical description of signs and symptoms of NDD, and if
there was medical confirmation of the event (i.e. patient
seen by appropriate individual with expertise to confirm
the diagnosis).
(18) Date/time of onset3, first observation4 and diagnosis5, dura-
tion and frequency of findings of NDD, last documented find-
ing6 and final outcome7.
(19) Concurrent signs, symptoms, and diseases.3 The
sympto
retrospe
4 The
for NDD
5 The
definitio
6 The
childho
the sub
7 E.g.
interven
8 An
the foll
inpatien
results
birth de Measurement/testing – Values and units of routinely
measured parameters (based on NDD testing tools) – in
particular those indicating the severity of the event;
 Method of measurement (e.g. type of assessor, type of
measurement tool, date and duration of measurement,
etc.);
 Results of laboratory examinations (glucose, electrolytes,
ultrasound. . .) surgical and/or pathological findings and
diagnoses if present and pertinent.(20) Treatment and/or interventions previously or currently
implemented for NDD, especially specify if drug(s) are used
and dosing.
(21) Outcome footnote 6 at last observation.
(22) Objective clinical evidence supporting classification of the
event as ‘‘serious”8.
(23) Maternal and infant exposures other than the maternal
immunization, including those 24 h before and after immu-
nization, until delivery, and before and after the identificationdate and/or time of onset is defined as the time when the first sign or
m indicative for NDD occurred. This may only be possible to determine in
ct.
date and/or time of first observation of the first sign or symptom indicative
can be used if date/time of onset is not known.
date of diagnosis of an episode is the day when the event met the case
n at any level.
end of the occurrence of NDD, related to spontaneous recovery in early
od and/or positive response to treatment/intervention, is defined as the time
ject no longer meets the case definition at the lowest level of the definition.
recovery to pre-event health status, spontaneous resolution, therapeutic
tion, persistence of the event, sequelae, death.
AEFI is defined as serious by international standards if it meets one or more of
owing criteria: 1) it results in death, 2) is life-threatening, 3) it requires
t hospitalization or results in prolongation of existing hospitalization, 4)
in persistent or significant disability/incapacity, 5) is a congenital anomaly/
fect, 6) is a medically important event or reaction.of the event (e.g. food, medications, environmental, etc.) con-
sidered potentially relevant to the reported event.
3.1.5. Miscellaneous/general
 The duration of surveillance for NDD should be predefined
based on the specific needs of the study.
Biologic characteristics of the vaccine (e.g. live attenuated ver-
sus inactivated component vaccines), biologic characteristics of
the vaccine-targeted disease, biologic characteristics of the vaccine
(e.g. nutrition, underlying disease like immune-depressing illness)
may be relevant for the choice of the duration of the surveillance
for Neurodevelopmental Delay.
(24) The duration of follow-up reported during the surveillance
period should be predefined. It should aim to continue to
resolution of the event, or its stabilization, as pertinent.
(25) Methods of data collection should be consistent within and
between study groups, if applicable.
(26) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1–24.
(27) Investigators of patients with NDD should provide guidance
to reporters to optimize the quality and completeness of
information provided.
(28) Reports of NDD should be collected throughout the study
period regardless of the time elapsed between maternal or
infant immunization and the adverse event. If this is not fea-
sible due to the study design, the study periods during which
safety data are being collected should be clearly defined.
3.2. Data analysis
The following guidelines represent a desirable standard for
analysis of data on NDD to allow for comparability of data, and
are recommended as an addition to data analyzed for the specific
study question and setting.
(29) Reported events should be classified in one of the following
five categories including the three LOC. Events that meet the
case definition should be classified according to the LOC as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional cat-
egories for analysis.
Event classification in 5 categories9
Event meets case definition
(1) Level 1: Criteria as specified in the NDD case
definition
(2) Level 2: Criteria as specified in the NDD case
definition
(3) Level 3: Criteria as specified in the NDD case
definition
Event does not meet case definition
Additional categories for analysis
(4) Level 4: Reported NDD with insufficient evidence to meet
the case definition109 The highest level of diagnostic certainty achieved for each domain should be
recorded.
10 If the evidence available for an event is insufficient because information is
missing, such an event should be categorized as ‘‘Reported Neurodevelopmental
Delay with insufficient evidence to meet the case definition”.
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(30) The interval between maternal immunization and reported
NDDcouldbedefinedas thedate/timeofmaternal immuniza-
tion to the date/time of onset footnote 2 of the first symptoms
and/or signs consistent with the definition. Additionally, the
occurrence of NDD in relation to the infant’s age should be
reported. If few cases are reported, the concrete time course
could be analyzed for each; for a large number of cases, data
can be analyzed in the following increments based on trime-
ster of maternal immunization, or infant’s age:
Subjects with Neurodevelopmental Delay by interval to presen-
tation in relation to trimester of maternal immunization and age
of the child.1
fin
shInterval*1 An event does not meet the case definition if investigation revea
ding of a necessary criterion (necessary condition) for diagnosis. S
ould be rejected and classified as ‘‘Not a case of NeurodevelopmentaNumberIn relation to maternal vaccination
First trimester
Second trimester
Third trimester
Any time during pregnancy
In relation to infant or child age
0–6 months of age
7–12 months
13–36 months of age
37–60 months of age
After 5 years of age
TOTAL(31) The duration of NDD could be analyzed as the interval between the date/-
time of onset footnote 1 of the first symptoms and/or signs consistent with
the definition and the last evaluation footnote 5 and/or final outcome foot-
note 6. Persistence beyond the last evaluation should be noted. Whatever
start and ending times are used, they should be used consistently within
and across study groups.
(32) If more than one measurement of a particular criterion is taken and
recorded, the value corresponding to the greatest magnitude of the adverse
experience could be used as the basis for analysis. Analysis may also include
other characteristics like qualitative patterns of criteria defining the event.
(33) The distribution of data (as numerator and denominator data) could be ana-
lyzed in predefined increments (e.g. measured values, times), where appli-
cable. Increments specified above should be used. When only a small
number of cases are presented, the respective values or time course can
be presented individually.
(34) Data on NDD obtained from subjects born to mothers receiving a vaccine
should be compared with those obtained from an appropriately selected
and documented control group(s) to assess background rates of hypersen-
sitivity in non-exposed populations, and should be analyzed by study arm
and dose where possible, e.g. in prospective clinical trials.
3.3. Data presentation
These guidelines represent a desirable standard for the presentation and publi-
cation of data on NDD in infants following maternal immunization to allow for
comparability of data, and are recommended as an addition to data presented for
the specific study question and setting. Additionally, it is recommended to refer
to existing general guidelines for the presentation and publication of randomized
controlled trials, systematic reviews, and meta-analyses of observational studies
in epidemiology (e.g. statements of Consolidated Standards of Reporting Trials
(CONSORT), of Improving the quality of reports of meta-analyses of randomized
controlled trials (QUORUM), and of Meta-analysis Of Observational Studies in Epi-
demiology (MOOSE), respectively) [176].
(35) All reported events of NDD should be presented according to the categories
listed in guideline 30 or other classification that is considered appropriate.ls a negative
uch an event
l Delay”.(36) Data on possible NDD events should be presented in accordance with data
collection guidelines 1–28 and data analysis guidelines 29–34.
(37) Terms to describe NDD such as ‘‘low-grade”, ‘‘mild”, ‘‘moderate”, ‘‘high”,
‘‘severe” or ‘‘significant” are highly subjective, prone to wide interpretation,
and should be avoided, unless clearly defined.
(38) Data should be presented with numerator and denominator (n/N) (and not
only in percentages), if available.
Although NDD safety surveillance systems denominator data are usually not
readily available, attempts should be made to identify approximate denominators.
The source of the denominator data should be reported and calculations of esti-
mates be described (e.g. manufacturer data like total doses distributed, reporting
through Ministry of Health, coverage/population based data, etc.).
(39) The incidence of cases in the study population should be presented and
clearly identified as such in the text.
(40) If the distribution of data is skewed, median and range are usually the more
appropriate statistical descriptors than a mean. However, the mean and
standard deviation should also be provided.
(41) Any publication of data on NDD in infants after maternal immunization
should include a detailed description of the methods used for data collec-
tion and analysis as possible. It is essential to specify:12 Use
respect
ration.o The study design;
 The method, frequency and duration of monitoring for NDD;
 The trial profile, indicating participant flow during a study including
drop-outs and withdrawals to indicate the size and nature of the
respective groups under investigation;
 The type of surveillance (e.g. passive or active surveillance);
 The characteristics of the surveillance system (e.g. population served,
mode of report solicitation);
 The search strategy in surveillance databases;
 Comparison group(s), if used for analysis;
 The instrument of data collection (e.g. standardized questionnaire,
diary card, report form);
 Whether the date of onset footnote 2 and/or the date of first observa-
tion footnote 3 and/or the date of diagnosis footnote 4 was used for
analysis; and
 Use of this case definition for NDD, in the abstract or methods section of
a publication12.4. Disclaimer
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